Allergy Immunotherapy Market Size, Trend, Forecast Report 2026 to 2035
What is Allergy Immunotherapy Market Size?
Global Allergy Immunotherapy Market Size is valued at USD 2.13 Billion in 2025 and is predicted to reach USD 4.76 Billion by the year 2035 at an 8.5% CAGR during the forecast period for 2026 to 2035.
Allergy Immunotherapy Market Size, Share & Trends Analysis Report by Treatment Type (SCIT, SLIT), By Allergy Type (Allergic Rhinitis, Asthma), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), Region And Segment Forecasts, 2026 to 2035.
Allergy Immunotherapy Market Key Takeaways:
|
Key Industry Insights & Findings from the Report:
- Investments in allergy immunotherapy research and development have been driven by the increasing healthcare expenditure worldwide, as well as the increased focus on customized medicine and targeted therapeutics.
- The rising incidence of allergic conditions such as allergic rhinitis, asthma, and atopic dermatitis has propelled the demand for allergy immunotherapy.
- With the increasing controversy around pharmaceutical treatments like corticosteroids and antihistamines, a growing number of individuals are looking for alternative therapies such as allergy immunotherapy, which offer longer-lasting benefits with lower prescription requirements.
- North America dominated the market and accounted for a global revenue share in 2024.
- The time-intensive nature of treatment might lead to poor patient adherence and dropout rates, impacting the effectiveness of therapy.
The COVID-19 pandemic is a rare health threat that is hurting people's lives, businesses, industries, and communities all across the world. Many businesses are still concentrating their research and development efforts on the creation of medicines against COVID-19 even if regulatory authorities have already approved their vaccines against the SARS-CoV-2 virus.
Healthcare providers continued to provide treatments or treatment advice during the pandemic since allergy patients require ongoing therapy and medication supply. For instance, it is advised that allergic patients who have asthma, rhinitis, atopic dermatitis, or chronic urticaria continue to receive maintenance therapy in a well-controlled manner during the pandemic, per the study titled "Management of Allergic Patients During the COVID-19 Pandemic in Asia" published in February 2021.
The key factors expediting the market's growth are the rising prevalence of different types of allergies and the introduction of innovative sublingual immunotherapies in emerging nations. One of the main drivers of the market is the rising burden of different forms of allergies. For instance, more than 50.0 million Americans suffer from an allergy of some sort each year, according to a journal article published by SingleCare in January 2022.
Additionally, it stated that allergies are the sixth most common chronic ailment in the US. According to a poll performed by SingleCare in 2021, 82.0% of respondents with allergies said their allergies have an impact on their quality of life in the US. In addition, the survey's findings revealed that 14.0% of respondents had experienced hospitalizations as a result of an allergic response. Because of this, it is projected that there will be an increase in the demand for allergy immunotherapy during the course of the projection period. But during the course of the projection period, it is anticipated that a lack of knowledge regarding allergies and treatments will restrain market expansion.
Competitive Landscape:
Some of the Allergy Immunotherapy market players are:
- ASIT Biotech
- Circassia
- Mylan N.V.
- Adamis Pharmaceuticals Corporation
- Merck KGaA
- Stallergenes Greer plc
- Allergy Therapeutics
- ALK-Abelló A/S
- DESENTUM OY
- HAL Allergy B.V.
- HollisterStier Allergy
- LETIPharma
- DBV Technologies SA
Market Segmentation:
The Allergy Immunotherapy market is segmented based on treatment type, allergy type, and distribution channel. Based on treatment type, the market is divided into Subcutaneous Immunotherapy (SCIT), Sublingual Immunotherapy (SLIT), Tablets, and Drops. The allergy type segment includes Allergic rhinitis, Allergic asthma, and Others. Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy are the segments by distribution channel.
Based On Treatment Type, The SCIT, Subcutaneous Immunotherapy Segment Is Accounted As A Major Contributor To The Allergy Immunotherapy Market
The main factor driving the segment is subcutaneous immunotherapy's (SCIT) excellent efficacy and cost-effectiveness. Subcutaneous immunotherapy (SCIT) is much more effective than sublingual immunotherapy (SLIT) drops or tablets in controlling symptoms of allergic rhinitis, according to a study titled "Efficacy of Subcutaneous and Sublingual Immunotherapy for House Dust Mite Allergy: A Network Meta-Analysis-Based Comparison" published in August 2021. Sublingual immunotherapy's (SLIT) excellent efficacy thus suggests that the product's demand would likely rise throughout the projected period, driving the segment's expansion.
The Hospital Pharmacy Segment Witnessed Growth At A Rapid Rate
Due to the increase in patients seeking treatment for allergic illnesses, the hospital pharmacy segment had the lion's share. For monitoring and treating any negative responses, allergy injections are typically administered at medical facilities or doctor's offices.
In The Region, The North America Allergy Immunotherapy Market Holds A Significant Revenue Share
Over the forecast period, North America is anticipated to dominate the market for allergy immunotherapy as a whole. Increased allergy cases and greater public awareness of allergy therapy are among the reasons contributing to the development. For instance, according to research released in May 2022 by the International Food Information Council, around 32.0 million Americans have reported having a food allergy, and every year, roughly 200,000 people seek emergency medical attention because of a food allergy. It also stated that food allergies were frequent in children, with one in every 13 kids in the US receiving a diagnosis, and that 40.0% of kids with food allergies were also allergic to other foods. It is anticipated that situations like these would increase the need for allergy immunotherapy in this area.
Recent Developments:
- In January 2024, Desentum, a biopharmaceutical business based in Finland, disclosed that it had secured €12 million in fundraising through a round organized by Springvest Oyj, an investment firm. Desentum announced that it will allocate the majority of these funds towards advancing the clinical development of a vaccine for birch pollen allergies and doing preclinical testing for a vaccine targeting peanut allergies.
- In July 2022, The good findings regarding the significant advantage of sublingual liquid allergen immunotherapy treatment (AIT) on the beginning and worsening of asthma in patients with allergic rhinitis was released by Stallergenes Greer, a worldwide healthcare firm that specializes in allergen immunotherapy (AIT).
Allergy Immunotherapy Market Report Scope:
| Report Attribute | Specifications |
| Market Size Value In 2025 | USD 2.13 Billion |
| Revenue Forecast In 2035 | USD 4.76 Billion |
| Growth Rate CAGR | CAGR of 8.5% from 2026 to 2035 |
| Quantitative Units | Representation of revenue in US$ Mn,and CAGR from 2026 to 2035 |
| Historic Year | 2022 to 2025 |
| Forecast Year | 2026-2035 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | Treatment Type, Allergy Type, And Distribution Channel |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
| Competitive Landscape | ASIT Biotech; Circassia; Mylan N.V.; Adamis Pharmaceuticals Corporation; Merck KGaA; Stallergenes Greer plc; Allergy Therapeutics; ALK-Abelló A/S; DESENTUM OY; HAL Allergy B.V.; HollisterStier Allergy; LETIPharma; DBV Technologies SA. |
| Customization Scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing and Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
Segmentation of Allergy Immunotherapy Market-
Allergy Immunotherapy Market By Treatment Type-
- Subcutaneous Immunotherapy (SCIT)
- Sublingual Immunotherapy (SLIT)
- Tablets
- Drops
Allergy Immunotherapy Market By Allergy Type-
- Allergic rhinitis
- Allergic asthma
- Others
Allergy Immunotherapy Market By Distribution Channel-
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Allergy Immunotherapy Market By Region-
North America-
- The US
- Canada
Europe-
- Germany
- The UK
- France
- Italy
- Spain
- Rest of Europe
Asia-Pacific-
- China
- Japan
- India
- South Korea
- South East Asia
- Rest of Asia Pacific
Latin America-
- Brazil
- Mexico
- Argentina
- Rest of Latin America
Middle East & Africa-
- GCC Countries
- South Africa
- Rest of the Middle East and Africa
Research Design and Approach
This study employed a multi-step, mixed-method research approach that integrates:
- Secondary research
- Primary research
- Data triangulation
- Hybrid top-down and bottom-up modelling
- Forecasting and scenario analysis
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary Research
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Sources Consulted
Secondary data for the market study was gathered from multiple credible sources, including:
- Government databases, regulatory bodies, and public institutions
- International organizations (WHO, OECD, IMF, World Bank, etc.)
- Commercial and paid databases
- Industry associations, trade publications, and technical journals
- Company annual reports, investor presentations, press releases, and SEC filings
- Academic research papers, patents, and scientific literature
- Previous market research publications and syndicated reports
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary Research
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Stakeholders Interviewed
Primary interviews for this study involved:
- Manufacturers and suppliers in the market value chain
- Distributors, channel partners, and integrators
- End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
- Industry experts, technology specialists, consultants, and regulatory professionals
- Senior executives (CEOs, CTOs, VPs, Directors) and product managers
Interview Process
Interviews were conducted via:
- Structured and semi-structured questionnaires
- Telephonic and video interactions
- Email correspondences
- Expert consultation sessions
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
Data Processing, Normalization, and Validation
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
- Standardization of units (currency conversions, volume units, inflation adjustments)
- Cross-verification of data points across multiple secondary sources
- Normalization of inconsistent datasets
- Identification and resolution of data gaps
- Outlier detection and removal through algorithmic and manual checks
- Plausibility and coherence checks across segments and geographies
This ensured that the dataset used for modelling was clean, robust, and reliable.
Market Size Estimation and Data Triangulation
Bottom-Up Approach
The bottom-up approach involved aggregating segment-level data, such as:
- Company revenues
- Product-level sales
- Installed base/usage volumes
- Adoption and penetration rates
- Pricing analysis
This method was primarily used when detailed micro-level market data were available.
Top-Down Approach
The top-down approach used macro-level indicators:
- Parent market benchmarks
- Global/regional industry trends
- Economic indicators (GDP, demographics, spending patterns)
- Penetration and usage ratios
This approach was used for segments where granular data were limited or inconsistent.
Hybrid Triangulation Approach
To ensure accuracy, a triangulated hybrid model was used. This included:
- Reconciling top-down and bottom-up estimates
- Cross-checking revenues, volumes, and pricing assumptions
- Incorporating expert insights to validate segment splits and adoption rates
This multi-angle validation yielded the final market size.
Forecasting Framework and Scenario Modelling
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Forecasting Methods
- Time-series modelling
- S-curve and diffusion models (for emerging technologies)
- Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
- Price elasticity models
- Market maturity and lifecycle-based projections
Scenario Analysis
Given inherent uncertainties, three scenarios were constructed:
- Base-Case Scenario: Expected trajectory under current conditions
- Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
- Conservative Scenario: Slow adoption, regulatory delays, economic constraints
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.
Request Customization
Add countries, segments, company profiles, or extend forecast — free 10% customization with purchase.
Customize This Report →Enquire Before Buying
Speak with our analyst team about scope, methodology, pricing, or deliverable formats.
Enquire Now →Frequently Asked Questions
Allergy Immunotherapy Market Size is valued at USD 2.13 Billion in 2025 and is predicted to reach USD 4.76 Billion by the year 2035.
Allergy Immunotherapy Market expected to grow at an 8.5% CAGR during the forecast period for 2026-2035.
ASIT Biotech; Circassia; Mylan N.V.; Adamis Pharmaceuticals Corporation; Merck KGaA; Stallergenes Greer plc; Allergy Therapeutics; ALK-Abelló A/S; DES
Allergy Immunotherapy market is segmented based on treatment type, allergy type, and distribution channel.
North America region is leading the Allergy Immunotherapy Market.